Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
interleukin 6
Biotech
Lilly pays CSL $100M for IL-6 drug that flunked transplant study
Lilly is paying $100 million for the right to develop a phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
James Waldron
Feb 18, 2026 5:07am
Tiziana to spin out IL-6 drug, cites pharma interest in modality
Dec 2, 2025 8:45am
Novartis spends $1.4B for Tourmaline, CV med that wowed in ph. 2
Sep 9, 2025 4:28am
I-Mab's IL-6 drug hits goal in ulcerative colitis phase 2
Apr 26, 2021 8:45am
Lassen Therapeutics, Cedars Sinai team up on lung fibrosis work
Mar 25, 2021 9:20am
Roche test OK’d to identify high-risk COVID-19 patients
Jun 4, 2020 10:50am
